Founder and former CEO Nick Arab to transition to CTO and focus on advancing Pattern’s single-cell microbiology technology
Austin, TX – January 9, 2025 – Pattern Bioscience, an innovator in rapid diagnostic technologies for bacterial infections, today announced that Carey-Ann Burnham, PhD, a leading microbiologist and Pattern’s chief clinical officer since 2022, has been appointed as the company’s new chief executive officer. Founder and former CEO Nick Arab has transitioned to the role of chief technology officer (CTO), where he will focus on advancing Pattern’s groundbreaking single-cell microbiology technology.
“Pattern is entering a pivotal phase as we advance into clinical validation and prepare to bring our transformative technology to market,” said Patrick Balthrop, Sr., chairman of Pattern’s board of directors. “Carey-Ann’s deep scientific expertise and proven leadership make her the ideal person to guide the company through this critical phase, ensuring we deliver on our mission to revolutionize the diagnosis of bacterial infections. Nick’s vision and leadership have been the foundation of Pattern’s success, and his continued focus on advancing our technology as CTO will be invaluable.”
This leadership transition comes at a pivotal moment for Pattern as the company progresses from the design and development phase to clinical validation of the first and only culture-free, rapid phenotypic microbial identification and susceptibility testing (ID/AST) platform to deliver clinically actionable results in hours.
“It’s an honor to take the helm of Pattern at such an important time,” said Dr. Burnham. “Our single-cell microbiology platform has the potential to revolutionize how bacterial infections are diagnosed and treated, and I look forward to working with our talented team to bring this technology to clinicians and patients who need it most.”
“Carey-Ann has been instrumental in Pattern’s success over the past two years,” said Nick Arab, Pattern’s founder and CTO. “As we move into the clinical validation phase, her unique combination of clinical expertise and operational acumen makes her the ideal leader to guide Pattern into its next phase. I’m excited to focus my efforts on ensuring our single-cell microbiology technology reaches its full potential.”
Dr. Burnham is a renowned microbiologist and a fellow of the American Academy of Microbiology, with more than 300 peer-reviewed publications to date. Before joining Pattern, she served as the medical director of clinical microbiology at Barnes-Jewish Hospital and professor of pathology & immunology, pediatrics, molecular microbiology, and medicine at Washington University in St. Louis. She is also the co-editor-in-chief of the Clinical Microbiology Procedures Handbook (5th edition) and the founding editor-in-chief of ASM Case Reports, a new journal from the American Society for Microbiology.
Under Burnham’s leadership, Pattern will focus on advancing its single-cell microbiology platform and launch assay, the Pneumonia ID/AST Panel, through clinical validation and regulatory submission. The platform is designed to deliver same-day results for pathogen identification and antibiotic susceptibility, addressing a critical need in the fight against antimicrobial resistance.
About Pattern Bioscience
Pattern Bioscience aims to save lives by transforming how bacterial infections are diagnosed and to improve global health by reducing the burden of antibiotic resistance. Its single-cell microbiology technology is the first and only culture-free, rapid phenotypic testing platform to deliver clinically actionable results in hours, compared to the days required by traditional culture-based methods. Pattern Bioscience is a privately held company based in Austin, Texas, and is led by veterans of the diagnostic industry with deep experience bringing new diagnostic technologies to market. For more information, visit pattern.bio.
For more information, please contact:
Contact: Kyle Fieleke
Email: kyle@pattern.bio
Website: pattern.bio